Community Trust Bancorp, Inc. Declares Its Cash Dividend

Community Trust Bancorp (NASDAQ:CTBI) announced a quarterly cash dividend of $0.53 per share, declared by the board on October 28, 2025.

(Low)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

dividends

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/29/2025 - 08:15 AM

PIKEVILLE, Ky.--(BUSINESS WIRE)-- On October 28, 2025, the Board of Directors of Community Trust Bancorp, Inc., (NASDAQ-CTBI) declared its quarterly cash dividend of $0.53 per share, which will be paid on January 2, 2025, to shareholders of record on December 15, 2025.

Community Trust Bancorp, Inc., with assets of $6.6 billion, is headquartered in Pikeville, Kentucky and has 72 banking locations across eastern, northeastern, central, and south central Kentucky, six banking locations in southern West Virginia, three banking locations in northeastern Tennessee, four trust offices across Kentucky, and one trust office in Tennessee.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251029611691/en/

For additional information please contact Mark A. Gooch, Chairman, President and CEO, Community Trust Bancorp, Inc. at (606) 437-3229

Source: Community Trust Bancorp, Inc.

Keep reading

More on CTBI

Jul 29, 2026 Community Trust Bancorp, Inc. Increases Its Cash Dividend
Jul 15, 2026 Community Trust Bancorp, Inc. Reports Record Earnings for the 2nd Quarter 2026
May 4, 2026 Community Trust Bancorp, Inc. Announces Planned Retirement of Bank President

All CTBI news

Trending in the feed

ARGX

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease Open the live feed